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Abstract Vitreous humor (VH) is an alternative matrix
for drug analysis in forensic toxicology. However, little is
known about the distribution of xenobiotics, such as opi-
oids, into VH in living organisms. The aim of this study
was to simultaneously measure heroin and metabolite
concentrations in blood and VH after injection of heroin in
a living pig model. Six pigs were under non-opioid anes-
thesia during the surgical operation and experiment. Ocular
microdialysis was used to acquire dialysate from VH, and a
venous catheter was used for blood sampling. Twenty
milligrams of heroin was injected intravenously with sub-
sequent sampling of blood and dialysate for 6 h. The
samples were analyzed by ultra-performance liquid chro-
matography–tandem mass spectrometry. Heroin was not
detected in VH; 6-monoacetylmorphine (6-MAM) and
morphine were first detected in VH after 60 min. The
morphine concentration in VH thereafter increased
throughout the experimental period. For 6-MAM, Cmax was
reached after 230 min in VH. In blood, 6-MAM reached
Cmax after 0.5 min, with a subsequent biphasic elimination
phase. The blood and VH 6-MAM concentrations reached
equilibrium after 2 h. In blood, morphine reached Cmax
after 4.3 min, with a subsequent slower elimination than
6-MAM. The blood and VH morphine concentrations were
in equilibrium about 6 h after injection of heroin. In con-
clusion, both 6-MAM and morphine showed slow transport
into VH; detection of 6-MAM in VH did not necessarily
reflect a recent intake of heroin. Because postmortem
changes are expected to be small in VH, these experimental
results could assist the interpretation of heroin deaths.
Keywords Heroin  Pharmacokinetic  Vitreous humor 
6-MAM  Ocular microdialysis  Pigs
Introduction
Heroin is a highly lipid soluble opioid prodrug with neg-
ligible affinity and efficacy to l-opioid receptor [1–3].
After intake, heroin is rapidly and completely converted to
6-monoacetylmorphine (6-MAM) spontaneously or by
serum and tissue cholinesterases, and by tissue car-
boxyesterases, among others. 6-MAM is further metabo-
lized to morphine that is in turn metabolized in the liver to
the inactive morphine-3-glucuronide (M3G) and the active
morphine-6-glucuronide (M6G), as well as several other
minor compounds (for reviews see [4–6]). In man, the
blood elimination half-life for heroin is less than 5 min, for
6-MAM around 15–20 min, for morphine 2–3 h, and for its
glucuronides, 4–6 h [7]. The most intense phase of heroin
effects, the ‘‘rush’’, takes place shortly after intake. At this
stage 6-MAM is the predominant metabolite in both blood
and brain [7–10]. Later, 1–2 h after intake, morphine and
M6G are the main metabolites able to mediate heroin’s
effects.
In forensic toxicology, results from postmortem body
fluids or tissues are used to interpret the role of drugs in
each death. Postmortem redistribution of drugs is a major
challenge in this interpretation, making the estimation of
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the true concentrations at the time of death difficult,
especially in cases with long postmortem intervals and
potentially substantial drug redistribution. Vitreous humor
(VH) is used as an alternative specimen for toxicological
interpretation, and it is assumed that this medium is less
prone to postmortem redistribution, making the detected
concentration more representative for the one present at the
time of death. When trying to estimate a blood concen-
tration from the one detected in VH, toxicologists fall
short, because no studies have investigated the kinetics of
heroin and metabolites in both blood and VH in vivo.
Therefore, the penetration and detection times for drugs
and metabolites in VH as compared to those in blood are
unknown.
In fatal cases where heroin metabolites are detected,
interpretation of the toxicological findings from different
specimens is especially important, because the presence of
metabolites and their concentrations can provide important
information not only about the cause of death, but also
about the time between intake of heroin and death. How
heroin and its metabolites distribute into different body
compartments after administration has previously been
well described for blood and urine in man [6]; the distri-
bution of heroin and its metabolites into the brain has been
also reported in animal models [8, 9, 11]. However, the
distribution into VH has been studied less thoroughly, and
such knowledge is important when interpreting the death
involving heroin.
Most previous studies investigating the distribution of
heroin and metabolites in both blood and VH have used
postmortem samples [12, 13]; antemortem in vivo kinetics
of drugs in VH have been studied for only a very few drugs
related to forensic toxicology in living animal models using
rabbits [14–16]. A study by Crandall et al. [17] compared
concentrations of morphine in VH and blood for one time
point in a porcine model. One of the main problems in the
study of the kinetics of drugs in VH is the limited amount
of VH available for sampling. This limits the number of
time points and forces the use of different animals for the
different time points increasing the spreading of the data.
Some of the challenges associated with sampling from VH
can be overcome by the use of ocular microdialysis, and
this technique has previously been used to investigate drug
distribution into the aqueous and vitreous body of the
rabbit eyes [18–21] (for review see Boddu et al. [22]).
With more antemortem knowledge about both blood and
VH kinetics of heroin and metabolites, the interpretation of
postmortem cases is easier and more exact. A better
understanding of the pharmacokinetics of these substances
in VH might further open new perspectives about the utility
of VH as a complementary sample in forensic toxicology.
The aim of this study was, therefore, to investigate the
concentration–time profiles of heroin, 6-MAM, morphine,
and M3G in both VH and blood after intravenous (i.v.)
administration in the living organism using ocular micro-
dialysis. This could further elucidate the usefulness of VH
as a forensic material. Pigs were chosen as the preferred
specimen for this study, because their physiology resem-
bles that of humans [23]. It is previously indicated that
formation of higher amounts of M3G could be expected in
pig as compared to those in humans, and formation of M6G
is not expected [24–26].
Materials and methods
Chemicals and reagents
Heroin hydrochloride, heroin-d3, 6-MAM, 6-MAM-d3,
6-MAM-d6, morphine-d3, M6G, M6G-d3, M3G, and M3G-
d3 were obtained from Lipomed (Lipomed GmbH, Arl-
sheim, Switzerland); morphine from NMD (NMD Gros-
sisthandel AS, Oslo, Norway); and morphine-d6 from
Toronto Research Chemicals Inc. (Toronto, Ontario,
Canada). Standard compounds were stored according to
supplier recommendations. HPLC-grade methanol and
acetonitrile were purchased from Labscan Ltd. (Poch SA,
Gliwice, Poland); analytical grade ammonium formate and
formic acid from Merck (Whitehouse Station, NJ, USA).
All water used was provided by a MilliQ A10 purification
system (Merck, Darmstadt, Germany). Stock and working
solutions were prepared as described previously [11].
Animals and conditions
Six Norwegian Landrace pigs (Sus scrofa domesticus) of
either sex (weight 45 ± 5 kg) supplied from the Centre for
Comparative Medicine, Oslo University Hospital, Rik-
shospitalet were used. They were housed separately at
standard housing conditions (08:00–20:00 lights on), with
free access to food and water. The experimental protocol
was approved by the Norwegian National Animal Research
Authority (Authorization Number 6425) and carried out in
accordance to Norwegian regulations and international
standards.
In vivo experiment
Anesthesia was induced with intramuscular (i.m.) injection
of ketamine (20 mg/kg), azaperone (3 mg/kg), and atropine
(0.02 mg/kg). The anesthesia was maintained with i.v.
ketamine (1–2 mg/kg) and pentobarbital (1–3 mg/kg) until
a tracheotomy through a neck midline incision was per-
formed, and the pig was mechanically ventilated by an
anesthesia machine (Leon plus, Heinen ? Lo¨wenstein;
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Bad Ems, Germany). Thereafter, general anesthesia was
continued by an infusion of ketamine (2–2.5 mg/kg/h)
together with inspired isoflurane at a concentration of
1.0–1.5 % using a Tec 7 gas analyzer (Heinen ? Lo¨wen-
stein). The inspired oxygen fraction was set to 0.35 and
ventilation adjusted to keep expired end-tidal carbon
dioxide concentration between 4.5 and 5.5 kPa. The right
internal jugular vein was cannulated with a triple lumen
central venous catheter (CVC) and advanced to vena cava
superior for pressure registration and for heroin adminis-
tration and blood sampling. The administration of heroin
and collection of blood samples were obtained from dif-
ferent lumens of the CVC to avoid cross contamination of
samples. The right carotid artery was cannulated for con-
tinuous blood pressure registration. A bladder catheter was
placed by a mini-laparotomy to extract urine samples and
measure diuresis and core temperature. Additional moni-
toring of the pig included electrocardiography, heart rate,
and SpO2. Fluid administration during the experiment was
made with i.v. Ringer’s acetate at a rate of 20 mL/kg/h.
A microdialysis guide cannula (AT6.14.iC, AgnTho´s,
Lidingo¨, Sweden) was carefully inserted into the eye
through a 19-gauge syringe needle. The needle was care-
fully inserted about 3 mm below the corneal scleral limbus
through the pars plana; the needle was then retracted and
the guide cannula inserted in its place. The guide dummy
was then retracted and the microdialysis probe (AT6.14.4,
AgnTho´s) was placed through the guide into the vitreous
body. The probe position was adjusted, by visual inspection
through the lens, such that the 4 mm long microdialysis
membrane (outer diameter, 0.6 mm) resided well sus-
pended in the mid-VH, and was then secured with surgical
tape (Fig. 1).
Before implantation of the microdialysis probe, the
probe was connected by fluorinated ethylene propylene-
tubing to a syringe containing a physiological Ringer´s
solution with deuterated recovery calibrators (6-MAM-d3,
morphine-d6, M3G-d3) for each compound under study.
The syringe containing the perfusion fluid was placed in a
syringe microinfusion pump (CMA 400; CMA Microdial-
ysis, Solna, Sweden). The pump perfusion flow was set to
0.7 lL/min. After implantation of the microdialysis probe
the pig received an i.v. bolus injection (2 mL) of 20 mg
heroin through the CVC, followed by flushing with 10 mL
physiological saline solution. Dialysate was collected at
10 min intervals, into vials containing 5 lL internal stan-
dards (ISs), during the entire experimental session. That is,
7 lL dialysate was collected per vial, giving a total sample
volume of 12 lL including the ISs. The vials were placed
in a fraction collector (CMA/470; CMA Microdialysis)
cooled to 6 C during collection. Concurrently, 0.1 mL
blood samples were taken through the CVC at 1, 2, 5, 7, 10,
15, 30, and then at every 30 min up to a maximum of
360 min after the injection of heroin. In one pig, samples
from the living pig were only taken until 180 min after the
injection, and postmortem samples were collected for
another 150 min (postmortem data is not included in the
succeeding data processing). In the remaining pigs, sam-
ples from the living animals were collected for
300–360 min after injection of heroin. The exact time point
for each sample was recorded.
Two samples from the VH, in the contralateral eye of
the one holding the microdialysis probe, were collected by
syringe aspiration at different time points during the
experiment. After euthanasia, and removal of the micro-
dialysis probe, an additional aspiration of VH was per-
formed from the eye holding the probe. The aspirated
samples were taken to compare to the microdialysis sam-
ples (dialysates).
The blood samples were prepared in accordance with a
previously established method with some modifications [9,
27]. In brief, blood samples were drawn using a syringe
and transferred to microcentrifuge tubes containing 100 lL
ammonium formate buffer (5 mM, pH 3.1) with 4 mg/mL
NaF and 17.8 IE/mL heparin sodium, handled on ice, and
immediately frozen on a freezing block at -80 C (placed
in a -80 C freezer overnight and placed on ice in a Sty-
rofoam box just before sampling). The block was switched
with a new block from the -80 C freezer after the first
60 min).
Each pig was finally euthanized by an i.v. injection of
1 g pentobarbital and 100 mmol potassium chloride
through the CVC.
Chemical analysis
Dialysate required no further sample preparation; the VH
sample analysis was done according to our previously
established method with minor modifications [11]. Briefly,
the samples were analyzed on a Waters Xevo TQ-S ultra-
performance liquid chromatography (UPLC)–tandem mass
Fig. 1 Microdialysis guide penetrating the pars plana with the probe
extending through the guide shaft into the vitreous chamber of the eye
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spectrometry (MS/MS) system equipped with an Aquity
HSS T3-column (Waters, Milford, MA, USA). This system
was more sensitive than the system used in Gottas et al.
[11]. We, therefore, determined new lowest levels of
detection (LODs) and lowest levels of quantification
(LLOQs) for 6-MAM, morphine, and M3G. Each LOD was
determined by evaluation of the signal/noise (S/N) ratio for
diluted series of the lowest standard, with an acceptance
criteria of S/N[ 3.
Sample preparation of the aspirated VH samples was
performed according to a previously published method
[27]; however, the chromatographic conditions were the
same as in the previously published method for urine [28].
Briefly, a 100-lL aliquot of VH was added 50 lL IS
solution (0.5 lM in water), and liquid-liquid extraction
with 500 lL acetonitrile/methanol (85:15) was performed.
Blood samples were prepared for analysis similarly to a
previously published method [27]. Briefly, 50 lL IS solu-
tion (0.5 lM in water) was added to the blood samples
before protein precipitation plus liquid–liquid extraction
with 500 lL acetonitrile/methanol (85:15). High-perfor-
mance liquid chromatography (HPLC)-MS/MS analysis
was performed with a Waters Quattro Premier coupled to a
XE MS/MS system equipped with a Xterra MS C18
column (150 9 2.1 mm internal diameter, 3.5 lm particle
size) (Waters). Chromatographic conditions were in
accordance with a previously established method [9].
Statistical analyses
Kinetica version 5.1 (Thermo Fisher Scientific Inc., Wal-
tham, MA, USA) was used for processing of the data.
Results are presented from fitting curves from this pro-
gram, in addition to individual data in some figures. The
compartment model was selected based on the best good-
ness of fit as determined by the lower Akaike Information
Criterion for each drug.
The calculated fitted results were used in a noncom-
partmental analysis to calculate the area under the con-
centration–time curve from time zero to last sample time
(AUCLast), the estimated maximum concentration (Cmax)
and the time, Tmax, to reach Cmax for all the different
substances. The half-lives (t1/2) were calculated for heroin,
6-MAM and morphine in blood. Additionally, t1/2 was
calculated for 6-MAM in VH. The AUC calculations were
based on a mixed log linear model implemented in the
Kinetica software, with an i.v. bolus model using the
extrapolated zero concentration functions for heroin in
blood after i.v. administration, and an extravascular model
for the metabolites in blood and all compounds in VH. All
data below LLOQ were discarded from the dataset before
processing in Kinetica.
Results
Validation of the analytical method
Although most analytical conditions were almost the same
as described previously [11], the UPLC-MS/MS system is
somewhat different and more sensitive. In the previous
report, the dialysate samples of rat brain extracellular fluid
were analyzed; in the present study, the dialysate samples
of pig VH were dealt with.
To check the sensitivity of the new instrumental system,
the lowest reference standard solutions were diluted down
to 6.0 pM; at this concentration the S/N ratios were as high
as 13.5, 58.3, and 6.0 for 6-MAM, morphine and M3G,
respectively. The performance of the lowest reference
standard (100 pM) determined the LLOQ. The variation
(% relative standard deviation) and accuracy (% bias) were
0.4 and 0.7 % for 6-MAM, 1.6 and 2.9 % for morphine,
and 9.6 and 6.0 % for M3G, respectively, at this concen-
tration, well within the widely accepted criteria of ±20 %
[29].
Recoveries for each microdialysis probes in VH were
calculated by retrodialysis using isotope analogs as descri-
bed by Gottas et al. [11]. This procedure was used for cal-
culating the concentration of unbound analyte in the VH. The
average recovery values for the deuterated recovery cali-
brators were 38 ± 9 % [mean ± standard deviation (SD)]
for 6-MAM-d3, 31 ± 6 % for morphine-d6 , and 28 ± 10 %
for M3G-d3 (n = 5 each).
The validation data for blood samples has been descri-
bed in our previous report [9].
Blood pharmacokinetics
The concentration-versus-time profiles of heroin and its
metabolites in blood and VH of pigs are shown in Fig. 2,
and the calculated pharmacokinetic parameters are listed in
Table 1. The heroin level in blood declined below LLOQ
already after about 15 min, with a biphasic concentration-
versus-time curve (Fig. 2a). The initial alpha phase (ultra-
rapid distribution, between 0 and 2 min) had an apparent
t1/2 of 0.4 min and the terminal elimination phase (between
5 and 15 min) a t1/2 of 1.9 min. The extrapolated C0 for
heroin was 116 lM. Based on the population-calculated
data, 6-MAM in blood reached a Cmax at 2.29 lM and Tmax
after 0.5 min. The decline in 6-MAM blood concentration
curve was also biphasic, with an initial alpha phase (be-
tween 0.5 and 5 min) with an apparent t1/2 of 2.0 min, and
a terminal elimination phase (between 30 and 270 min)
with a t1/2 of 27.2 min (Fig. 2b). In the alpha phase, heroin
was still present and, therefore, influenced the concentra-
tion curve for 6-MAM, whereas virtually all heroin was
280 Forensic Toxicol (2016) 34:277–285
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Fig. 2 Blood and vitreous









different animals), lines show
the fitted values calculated in
the Kinetica software. a–
d Observed and fitted values for
each separate compound in
blood (n = 6) (for heroin,
n = 5). e–g Observed and fitted
values for each separate
compound in VH (n = 5)
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cleared from the blood during the terminal elimination
phase. The morphine concentrations increased gradually,
with a Cmax of 0.37 lM after 4.3 min (Tmax) (Fig. 2c).
Morphine further had a t1/2 of 109 min in the terminal
elimination phase between 270 and 360 min, i.e. when no
6-MAM was detected in blood. The blood levels of M3G
increased even slower than morphine, with a Cmax of
1.36 lM after 20.2 min (Tmax) (Fig. 2d).
Ocular/vitreous humor pharmacokinetics
The concentration-versus-time profiles in VH are also
shown in Fig. 2, and the calculated pharmacokinetic
parameters are listed in Table 1. Heroin was not detected in
VH dialysate. 6-MAM appeared in VH dialysate 56.8 min
(range 20–80 min) after injection of heroin. Thereafter the
6-MAM concentrations increased gradually and reached a
Cmax of 0.0238 lM after 230 min (Tmax) (Fig. 2e). The
apparent t1/2 for 6-MAM was 336 min. Similarly to
6-MAM, morphine was first detected in VH 57.2 min
(range 30–100 min) after the heroin injection. Thereafter,
the concentration increased gradually throughout the
experimental procedure to reach a concentration of
0.0217 lM after 360 min (Fig. 2f). M3G first appeared in
VH after about 85.9 min (range 60–240 min), thereafter
the levels increased slightly during the total experimental
procedure to reach a concentration of 0.0028 lM after
360 min (Fig. 2g).
To show the microdialysis technique superiority over
traditional aspiration, aspirated VH samples were also
collected. A total of 18 VH samples were collected by
aspiration. Only eight of these did not show too much
contamination by blood, making the results reliable. For
these samples, the mean concentration ratio of aspirated
samples to dialysates at the same time point were 2.4 ± 1.8
(mean ± SD) for morphine and 2.1 ± 3.0 for 6-MAM.
The results from aspirated samples were not used any
further, because of the possible blood contamination.
Relationship between drug concentrations in blood
and vitreous humor
The blood/VH concentration ratio for morphine according
to the fitted curve was 160 after 1 h, 7 after 2 h and
decreased to approximately 1 after 6 h (Fig. 2c, f). The
blood/VH concentration ratio for 6-MAM according to the
fitted curve was 64 after 1 h, 1 after 2 h and B1 for the
remaining experimental period (Fig. 2b, e). The blood/VH
concentration ratio for M3G was[100 for the total
experimental period (Fig. 2d, g).
Discussion
This study described the transfer of heroin metabolites into
VH. To our knowledge, this is the first pharmacokinetic
study on heroin metabolites in both blood and VH in the
living animal. We observed a slow distribution from blood
to VH for all of the heroin metabolites studied; heroin,
however, was not detected in the VH. Importantly, the
interval when 6-MAM can be detected was much longer in
VH as compared to that in blood.
The strength of the present study is the tracing of the
concentrations of heroin metabolites in VH in detail in a
living animal. This was made possible by the use of the
microdialysis technique, without regular aspiration
demanding a large number of animals and incurring a high
probability of blood contamination of the samples. Macha
and Mitra [30] stated that microdialysis was superior to
direct sampling techniques and could be applied to study
ocular drug pharmacokinetics without rendering consider-
able physiological changes to the ocular barriers and the
intraocular environment. We chose the pig model because
it resembles the human being in both size and physiology
[23, 31], and we found that the blood pharmacokinetics
were comparable to data previously published on humans
[6]. From the literature, it has also been indicated that
glucuronidation and esterase-mediated hydrolysis in pigs is
expected not to differ substantially from those of humans
Table 1 Pharmacokinetic parameters for blood and vitreous humor
(VH) dialysate after intravenous injection of 20 mg heroin to each pig
Drug Parameter Blood VH dialysate
Heroin AUCLast [lM 9 min] 26.4 –
C0 (lM) 116
a –
Tmax (min) 0.0 –
T1/2 alpha-phase (min) 0.4 –
T1/2 elimination-phase (min) 1.9 –
6-MAM AUCLast [lM 9 min] 18.7 5.9
Cmax (lM) 2.29 0.0238
Tmax (min) 0.5 230
T1/2 alpha-phase (min) 2.0 –
T1/2 elimination-phase (min) 27.2 336
Morphine AUCLast [lM 9 min] 26.1 4.9
Cmax (lM) 0.37 0.0217
b
Tmax (min) 4.3 360
b
T1/2 elimination-phase (min) 109 –
M3G AUCLast [lM 9 min] 285 0.5
Cmax (lM) 1.36 0.0028
b
Tmax (min) 20.2 360
b
All parameters are based on population simulation data in Kinetica
a C0 calculated in Kinetica must be considered as uncertain
b Cmax and Tmax at the end of experiment presented
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[24, 25, 32]. One weakness of this model is the lack of
formation of M6G, which is also used in the interpretation
of postmortem cases. There was also some inconsistency in
the experimental period with sampling from the living
animal, because it was prolonged as compared with the
handling of postmortem samples, after we discovered the
slow transfer to VH in the first pig. In the first pig, where
postmortem samples were also collected for 150 min after
death, the blood/VH concentration ratios of 6-MAM,
morphine, and M3G continued to fall during the post-
mortem period (data not shown). This needs to be studied
in more detail. The results in the present study were quite
consistent among the animals, with only one pig showing
higher concentrations of 6-MAM and M3G in VH (shown
by dark blue circles in Fig. 2e, g), but not in blood (Fig. 2b,
d). These findings might reflect the fact that individual
differences in penetration could be expected, but their
prolonged detection times in VH were still to be expected.
Our results are in accordance with the limited previ-
ous studies on kinetics of drugs of abuse in VH. In rabbit
models, equilibrium between blood and VH for ethanol
after its i.v. administration was attained after 10–20 min
[14], for diazepam 60–120 min after its i.m. adminis-
tration [15], and for MDMA 30 and 120 min after its i.m.
administration [16]. Crandall et al. [17] reported that
morphine appeared in the aspirated VH 20 min after i.v.
administration of a fatal dose (about 120 mg) of mor-
phine using a pig model. However, in our experience, it
was difficult to avoid blood contamination of the aspi-
rated VH samples, and we believe that it cannot be
excluded that the results presented by Crandall et al. [17]
are influenced by blood contamination. We also
observed early and high levels of both morphine and
M3G in our aspirated blood-contaminated VH samples
(data not shown).
Although the pharmacokinetics of opioids in VH in vivo
has not previously been studied in detail, a number of
previous studies have investigated on the postmortem
relationship between blood and VH concentrations for
different drugs. Our results could explain the findings in
two previous studies regarding heroin metabolite ratios of
blood to VH. Bogusz et al. [12] compared concentrations in
femoral blood versus VH in 12 human cases where deaths
were attributed to intoxication with heroin. The concen-
trations of morphine were generally lower in VH than in
blood, and they found a mean ratio of blood/VH of 4.2 for
morphine; 6-MAM was most often not detected, or only
trace amounts were found in either blood or VH (LOD
0.5 ng/mL). They concluded that lower concentrations of
morphine and its glucuronides in VH as compared to those
in femoral blood might reflect a slower distribution of
drugs to VH, which was verified in our study (Fig. 2c, d, f,
g) [12]. Wyman and Bultman [13] investigated 25 autopsy
cases identified as heroin exposures. They also found
concentrations of morphine higher in femoral blood than in
VH, with a mean blood/VH concentration ratio of 3.5. For
6-MAM, however, they found that its concentrations in
VH, in general, were higher than in femoral blood, with a
blood/VH concentration ratio of 0.2. They concluded that
the possibility of detecting 6-MAM in postmortem speci-
mens could be greatly improved when VH was included as
a specimen for analysis in such cases [13]. This conclusion
was strengthened by the experimental data in the present
study (Fig. 2b, e), because the concentration of 6-MAM in
VH exceeded the one in blood at a relatively early time
point for 6-MAM, as compared with morphine as shown in
Fig. 2b, e.
The present results raise questions about the physiology
of transfer of drugs from blood into VH. The entry of
systemic administered drugs into the VH is prevented by
different barriers, e.g., the blood-aqueous barrier and the
blood-retina barrier (BRB) [22, 33]. The penetration of
drugs through membranes, including the BRB, depends on
their size, shape, charge, and lipophilicity [34, 35]. The
flow is further governed by hydrostatic and osmotic pres-
sure, as well as the concentration differences across the
membrane [34]. The differences in penetration into VH
observed between drugs have been attributed also to pro-
tein-binding of the drugs studied [36]. VH is low in pro-
teins, with only 1–3 % of the total serum protein
concentration [16], and we assume that there are no rele-
vant differences between humans and pigs in this regard.
The protein binding of morphine in pig and human plasma
does not show significant differences [37].
As seen in Fig. 2, a delay in diffusion was observed for
all of the opioids under study, and especially for 6-MAM,
its concentration in VH still increased after the concen-
tration in blood became very low (Fig. 2b, e). Even though
the mechanisms for this finding are not fully understood,
some theories can be launched. It has been suggested that
the cornea may act as a reservoir for drugs [21]; further-
more, some drugs might have an affinity for melanin pig-
ment present outside the retina [38–40], possibly both
delaying and prolonging the distribution of drugs into
different compartments of the eye (for reviews see Gau-
dana et al. [41] and Be´valot et al. [42]). In a study by
Pitkanen et al. [40], the most lipophilic beta blockers
showed the highest permeability coefficients through the
outer BRB; moreover, the longest VH diffusion time
(permeation lag time) was seen for the most lipophilic
drugs. They also suggested that this might be due to an
increasing drug-melanin binding with increasing
lipophilicity, because these drugs showed the greatest
binding to melanin [39]. Whether the theories mentioned
above also apply to the opioids in this study is only spec-
ulative; however, the binding of opioids to melanin in hair
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has been documented [43]. Regarding the prolonged
detection times for 6-MAM, it was previously suggested
that esterases in VH showed lower activities and were more
saturable as compared with those in blood [44, 45]. The
mechanisms behind the decline in concentrations of mor-
phine in VH have not previously been described, but it
should be noted that prolonged detection times were
observed for all of the metabolites.
How can our results assist in the practical interpretation
of postmortem cases, considering the fact that drug con-
centrations in VH are expected to be subject to fewer
postmortem changes [36, 46]? If the approximate time frame
between intake and death is known, the true antemortem
blood concentration could be calculated based on the con-
centration in the VH. Often, a very high blood concentration
of morphine is seen together with a low concentration in
VH, which might represent the true antemortem situation if
death occurred within the first hour after intake of heroin;
however, if some hours had elapsed, which is often the case
with heroin deaths, the true antemortem blood morphine
concentration would be expected to be closer to or lower
than the morphine concentration observed in the VH.
Based on the final measured concentrations and the half-
lives of 6-MAM, in the present study, the expected
detection time for 6-MAM in VH could be more than 20 h
in a living subject. Assuming limited postmortem changes
in VH [36, 46], the detection of 6-MAM in VH postmortem
could indicate that death occurred as many as 20 h or more
after an intake of heroin. The dose and the LLOQ may, of
course, influence this estimate. In postmortem cases, a
negative 6-MAM in blood together with a positive 6-MAM
in VH is often observed. In light of our findings, this could
be explained by the considerably longer detection times for
6-MAM in VH as compared to those in blood. Because the
present study also indicated longer detection times for
morphine in VH, as compared to those in blood, it can be
assumed that the detection times for other drugs are also
longer in VH, as compared to those in blood.
It has previously been reported that a high blood/VH
concentration ratio of drugs suggest rapid death [42]. The
results from the present study could argue that the detection
of 6-MAM or morphine in VH indicates that death did not
occur within the first hour after intake of heroin. This
finding is, however, complicated by the fact that heroin is
often used on a daily basis, and therefore, detections in VH
could be caused by intake, for instance, on the day before.
Conclusions
To our knowledge, this is the first report dealing with a
pharmacokinetic study on heroin metabolites in VH using a
living pig model. The pig resembles the human in both size
and physiology except from minor metabolic species dif-
ferences. To get pharmacokinetic data from VH samples,
the present microdialysis sampling using the pig model is
most recommended. Such data of heroin metabolites
obtained from the blood and VH samples collected from
living pigs gave an important clue for interpretation of
antemortem heroin poisoning in human victims by the
postmortem analysis of heroin metabolites in both blood
and VH samples.
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